Tamayo Carmen
Flora Inc. USA, Bethesda, Maryland 20817, USA.
Clin Infect Dis. 2008 Feb 1;46 Suppl 2:S101-3; discussion S144-51. doi: 10.1086/523332.
Although there exists some evidence of the safety and efficacy of probiotics for treatment of disease, many of the clinical trials have lacked methodological quality, particularly with regard to protocol design, selection of population, and product characterization. Depending on the regulatory route, data need to be collected carefully to satisfy regulatory requirements in the United States and elsewhere. This article discusses how the regulations for probiotics affect clinical research. It also describes clinical trial design and issues that affect the design of trials for probiotics conducted to improve the scientific evidence for these products.
尽管有一些证据表明益生菌治疗疾病具有安全性和有效性,但许多临床试验在方法学质量上存在欠缺,尤其是在方案设计、人群选择和产品特性描述方面。根据监管途径的不同,需要谨慎收集数据以满足美国和其他地区的监管要求。本文讨论了益生菌相关法规如何影响临床研究。它还描述了临床试验设计以及影响益生菌临床试验设计的问题,这些试验旨在为这些产品提供更科学的证据。